{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:41:37Z","timestamp":1790757697200,"version":"4.1.0"},"reference-count":201,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Peripheral neurologic complications are frequent adverse events during oncologic treatments and often lead to dose reduction, administration delays with time elongation of the therapeutic plan and, not least, worsening of patients\u2019 quality of life. Experience skills are required to recognize symptoms and clinical evidences and the collaboration between different health professionals, in particular oncologists and hospital pharmacists, grants a correct management of this undesirable occurrence. Some classes of drugs (platinates, vinca alkaloids, taxanes) typically develop this kind of side effect, but the genesis of chemotherapy-induced peripheral neuropathy is not linked to a single mechanism. This paper aims from one side at summarizing and explaining all the scattering mechanisms of chemotherapy-induced peripheral neuropathy through a detailed literature revision, on the other side at finding new approaches to possible treatments, in order to facilitate the collaboration between oncologists, hematologists and hospital pharmacists.<\/jats:p>","DOI":"10.3390\/ijms22041980","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T21:35:42Z","timestamp":1613597742000},"page":"1980","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms"],"prefix":"10.3390","volume":"22","author":[{"given":"Mariarita","family":"Laforgia","sequence":"first","affiliation":[{"name":"Pharmacy Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5074-4951","authenticated-orcid":false,"given":"Carmelo","family":"Laface","sequence":"additional","affiliation":[{"name":"Interventional and Medical Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco65, 70124 Bari, Italy"},{"name":"Department of Biomedical Sciences and Human Oncology, University of Bari \u2018Aldo Moro\u2019, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ferraiuolo","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ungaro","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Tricarico","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosmo Damiano","family":"Gadaleta","sequence":"additional","affiliation":[{"name":"Interventional and Medical Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8779-1957","authenticated-orcid":false,"given":"Patrizia","family":"Nardulli","sequence":"additional","affiliation":[{"name":"Pharmacy Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco 65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Ranieri","sequence":"additional","affiliation":[{"name":"Interventional and Medical Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Viale Orazio Flacco65, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.neuron.2013.07.051","article-title":"The Sensory Neurons of Touch","volume":"79","author":"Abraira","year":"2013","journal-title":"Neuron"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jpainsymman.2006.12.010","article-title":"Chemosensory Changes Experienced by Patients Undergoing Cancer Chemotherapy: A Qualitative Interview Study","volume":"34","author":"Bernhardson","year":"2007","journal-title":"J. Pain Symptom Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11764-014-0379-x","article-title":"Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer","volume":"9","author":"Jones","year":"2014","journal-title":"J. Cancer Surviv."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00558","DOI":"10.1002\/brb3.558","article-title":"Chemotherapy-induced neuropathies-a growing problem for patients and health care providers","volume":"7","author":"Banach","year":"2016","journal-title":"Brain Behav."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1418-3","article-title":"Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: A case-controlled feasibility study","volume":"15","author":"Adams","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5302-4","article-title":"Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy","volume":"19","author":"Molassiotis","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zaj\u0105czkowska, R., Kocot-K\u0119pska, M., Leppert, W., Wrzosek, A., Mika, J., and Wordliczek, J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061451"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum Neurotoxicity Pharmacogenetics","volume":"8","author":"Mcwhinney","year":"2009","journal-title":"Mol. Cancer."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Park, S.B., Kwok, J.B., Loy, C.T., Friedlander, M.L., Lin, C.S., Krishnan, A.V., and Kiernan, M.C. (2014). Paclitaxel-Induced Neuropathy: Potential Association of MAPT and GSK3B Genotypes. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-993"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide Sensory Neurotoxicity: A Clinical and Neurophysiologic Study","volume":"62","author":"Cavaletti","year":"2004","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/01.wnl.0000267271.18475.fe","article-title":"Neuropathy in Multiple Myeloma Treated with Thalidomide: A Prospective Study","volume":"69","author":"Plasmati","year":"2007","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1007\/s00520-012-1384-0","article-title":"Ixabepilone-Associated Peripheral Neuropathy: Data from Across the Phase II and III Clinical Trials","volume":"20","author":"Vahdat","year":"2012","journal-title":"Supportive Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","article-title":"Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects","volume":"288","author":"Gornstein","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fphar.2013.00156","article-title":"Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN)","volume":"4","author":"Han","year":"2013","journal-title":"Front. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: A comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s11910-017-0757-7","article-title":"Update on Chemotherapy-Induced Peripheral Neuropathy","volume":"17","author":"Cioroiu","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/jco.2015.33.28_suppl.90","article-title":"Predictors of chemotherapy-induced peripheral neuropathy among breast cancer patients treated with taxanes","volume":"33","author":"Candelario","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"1175","article-title":"Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: A single-center retrospective study","volume":"24","author":"Kalender","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrneurol.2012.97","article-title":"Small-fibre neuropathies\u2014advances in diagnosis, pathophysiology and management","volume":"8","author":"Hoeijmakers","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuropharm.2013.08.016","article-title":"The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions","volume":"76","author":"Gornstein","year":"2014","journal-title":"Neuropharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/j.1460-9568.2011.07652.x","article-title":"Terminal arbor degeneration\u2014A novel lesion produced by the antineoplastic agent paclitaxel","volume":"33","author":"Bennett","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0896-6273(02)00908-X","article-title":"P38 MAPK Activation by NGF in Primary Sensory Neurons After In-flammation Increases TRPV1 Levels and Maintains Heat Hyperalgesia","volume":"36","author":"Ji","year":"2002","journal-title":"Neuron"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nurt.2009.07.008","article-title":"Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain","volume":"6","author":"Wu","year":"2009","journal-title":"Neurotherapy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbi.2015.06.003","article-title":"MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy","volume":"49","author":"Li","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_31","first-page":"371","article-title":"Update on taxane development: New analogs and new formulations","volume":"6","author":"Tkaczuk","year":"2012","journal-title":"Drug Des. Dev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1545968319860486","article-title":"Neuropathic Pain in Taxane-Induced Peripheral Neuropathy: Evidence for Exercise in Treatment","volume":"33","author":"Hammond","year":"2019","journal-title":"Neurorehabilit. Neural Repair"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jpain.2009.04.006","article-title":"Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated with Paclitaxel","volume":"10","author":"Morrow","year":"2009","journal-title":"J. Pain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","volume":"125","author":"Hershman","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mus.21874","article-title":"Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy","volume":"43","author":"Park","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e12407","DOI":"10.1111\/ecc.12407","article-title":"Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: A meta-analysis","volume":"26","author":"Peng","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2006.01.037","article-title":"Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction","volume":"122","author":"Flatters","year":"2006","journal-title":"Pain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.critrevonc.2015.04.011","article-title":"Taxane induced neuropathy in patients affected by breast cancer: Literature review","volume":"96","author":"Taglieri","year":"2015","journal-title":"Crit. Rev. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/toxics3020152","article-title":"Taxane-Induced Peripheral Neurotoxicity","volume":"3","author":"Velasco","year":"2015","journal-title":"Toxics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/srep06370","article-title":"Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl\/6 mice","volume":"4","author":"Boehmerle","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.expneurol.2006.05.007","article-title":"Paclitaxel- and vincristine-evoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cells","volume":"201","author":"Siau","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2011.12.023","article-title":"Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel","volume":"203","author":"Xiao","year":"2012","journal-title":"Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jpain.2016.02.011","article-title":"Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy","volume":"17","author":"Zhang","year":"2016","journal-title":"J. Pain"},{"key":"ref_45","first-page":"75","article-title":"Paclitaxel-induced neuropathic pain is age dependent and devolves on glial response","volume":"17","author":"Baulies","year":"2012","journal-title":"Eur. J. Pain"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1744-8069-6-76","article-title":"Prevention of Paclitaxel-Induced Allodynia by Minocycline: Effect on Loss of Peripheral Nerve Fibers and Infiltration of Macrophages in Rats","volume":"6","author":"Liu","year":"2010","journal-title":"Mol. Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/j.intimp.2003.08.007","article-title":"The immunopharmacology of paclitaxel (Taxol\u00ae), docetaxel (Taxotere\u00ae), and related agents","volume":"3","author":"Fitzpatrick","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1074\/jbc.M106802200","article-title":"Paclitaxel Affects Cytosolic Calcium Signals by Opening the Mitochondrial Permeability Transition Pore","volume":"277","author":"Kidd","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2016.06.050","article-title":"Oxidative stress in the development, maintenance and resolution of paclitaxel-induced painful neuropathy","volume":"333","author":"Duggett","year":"2016","journal-title":"Neurosci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuroscience.2011.10.010","article-title":"Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat","volume":"199","author":"Xiao","year":"2011","journal-title":"Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.pain.2011.12.011","article-title":"Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin","volume":"153","author":"Xiao","year":"2012","journal-title":"Pain"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/ALN.0000000000000176","article-title":"Enhanced Excitability of Primary Sensory Neurons and Altered Gene Expression of Neuronal Ion Channels in Dorsal Root Ganglion in Paclitaxel-induced Peripheral Neuropathy","volume":"120","author":"Zhang","year":"2014","journal-title":"Anesth."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.pain.2013.02.023","article-title":"Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion","volume":"154","author":"Hara","year":"2013","journal-title":"Pain"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00424-011-1071-x","article-title":"TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism","volume":"463","author":"Materazzi","year":"2012","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.neuroscience.2011.06.085","article-title":"Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain","volume":"193","author":"Chen","year":"2011","journal-title":"Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1523\/JNEUROSCI.0899-17.2017","article-title":"DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain","volume":"38","author":"Li","year":"2018","journal-title":"J. Neurosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2011.08.016","article-title":"Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy","volume":"232","author":"Zheng","year":"2011","journal-title":"Exp. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10048-012-0313-1","article-title":"Vincristine exacerbates asymptomatic Charcot\u2013Marie\u2013Tooth disease with a novel EGR2 mutation","volume":"13","author":"Nakamura","year":"2012","journal-title":"Neurogenetics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/1097-0142(19901015)66:8<1697::AID-CNCR2820660808>3.0.CO;2-G","article-title":"Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin","volume":"66","author":"Huinink","year":"1990","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2003.09.035","article-title":"Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients with Advanced Metastatic Germ Cell Cancer: An Extended Phase I\/II Study of the German Testicular Cancer Study Group","volume":"21","author":"Schmoll","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/brain\/awl356","article-title":"Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies","volume":"130","author":"Schmalbruch","year":"2006","journal-title":"Brain"},{"key":"ref_63","first-page":"2192","article-title":"Cisplatin Neuropathy","volume":"61","author":"Mollman","year":"1988","journal-title":"Risk Factors, Prognosis, and Protection by WR-2721. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Leonard, G.D., A Wright, M., Quinn, M.G., Fioravanti, S., Harold, N., Schuler, B., Thomas, R.R., and Grem, J.L. (2005). Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer, 5.","DOI":"10.1186\/1471-2407-5-116"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4185-0","article-title":"The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review","volume":"18","author":"Gebremedhn","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.pain.2013.05.032","article-title":"An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways","volume":"154","author":"Deuis","year":"2013","journal-title":"Pain"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","article-title":"Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study","volume":"144","author":"Attal","year":"2009","journal-title":"Pain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/annonc\/mdp594","article-title":"Capecitabine combined with oxaliplatin (CapOx) in clinical practice: How significant is peripheral neuropathy?","volume":"21","author":"Storey","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1188\/11.CJON.182-188","article-title":"Peripheral Neuropathy in Patients With Colorectal Cancer Receiving Oxaliplatin","volume":"15","author":"Tofthagen","year":"2011","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility","volume":"16","author":"Park","year":"2011","journal-title":"Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Selvy, M., Pereira, B., Kerckhove, N., Gonneau, C., Feydel, G., P\u00e9torin, C., Vimal-Baguet, A., Melnikov, S., Kullab, S., and Hebbar, M. (2020). Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082400"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/0284186X.2014.980912","article-title":"Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry","volume":"54","author":"Beijers","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer","volume":"18","author":"Figer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity","volume":"119","author":"Argyriou","year":"2012","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/COC.0b013e318246b50d","article-title":"Predicting Acute and Persistent Neuropathy Associated With Oxaliplatin","volume":"36","author":"Alejandro","year":"2013","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/ajco.12694","article-title":"Factors associated with the development and severity of oxaliplatin-induced peripheral neuropathy: A systematic review","volume":"13","author":"Pulvers","year":"2017","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_78","first-page":"3157","article-title":"Association of Voltage-Gated Sodium Channel Genetic Polymorphisms with Oxaliplatin-Induced Chronic Peripheral Neuropathy in South Indian Cancer Patients","volume":"18","author":"Palugulla","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","article-title":"Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons","volume":"41","author":"Podratz","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2018.03.007","article-title":"Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function","volume":"120","author":"Yang","year":"2018","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.phrs.2018.09.031","article-title":"PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection","volume":"137","author":"McQuade","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ranieri, G., Laforgia, M., Nardulli, P., Ferraiuolo, S., Molinari, P., Marech, I., and Gadaleta, C.D. (2019). Oxaliplatin-Based Intra-arterial Chemotherapy in Colo-Rectal Cancer Liver Metastases: A Review from Pharmacology to Clinical Application. Cancers, 11.","DOI":"10.3390\/cancers11020141"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jpain.2008.01.335","article-title":"Oxaliplatin Acts on IB4-Positive Nociceptors to Induce an Oxidative Stress-Dependent Acute Painful Peripheral Neuropathy","volume":"9","author":"Joseph","year":"2008","journal-title":"J. Pain"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpain.2011.11.009","article-title":"Oxaliplatin-Induced Neuropathy: Oxidative Stress as Pathological Mechanism. Protective Effect of Silibinin","volume":"13","author":"Mannelli","year":"2012","journal-title":"J. Pain"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuropharm.2018.07.026","article-title":"Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin","volume":"140","author":"Poupon","year":"2018","journal-title":"Neuropharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/emmm.201100134","article-title":"Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors","volume":"3","author":"Descoeur","year":"2011","journal-title":"Embo Mol. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.taap.2018.01.001","article-title":"Neurotoxic effect of oxaliplatin: Comparison with its oxalate-free analogue cis-[PtII(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato)] (LLC-1402) in mice","volume":"340","author":"Pereira","year":"2018","journal-title":"Toxicol. Appl. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jnc.14607","article-title":"Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy","volume":"148","author":"Fujita","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbi.2014.08.010","article-title":"Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy","volume":"44","author":"Janes","year":"2015","journal-title":"BrainBehav. Immun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00280-013-2304-9","article-title":"Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice","volume":"73","author":"Park","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Xu, D., Zhao, H., Gao, H., Zhao, H., Liu, D., and Li, J. (2018). Participation of pro-inflammatory cytokines in neuropathic pain evoked by chemotherapeutic oxaliplatin via central GABAergic pathway. Mol. Pain, 14.","DOI":"10.1177\/1744806918783535"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Li, Y.-Y., Li, H., Liu, Z.-L., Li, Q., Qiu, H.-W., Zeng, L.-J., Yang, W., Zhang, X.-Z., and Li, Z.-Y. (2017). Activation of STAT3-mediated CXCL12 up-regulation in the dorsal root ganglion contributes to oxaliplatin-induced chronic pain. Mol. Pain, 13.","DOI":"10.1177\/1744806917747425"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Wang, J., Zhang, X.-S., Tao, R., Zhang, J., Liu, L., Jiang, Y.-H., Ma, S.-H., Song, L.-X., and Xia, L.-J. (2017). Upregulation of CX3CL1 mediated by NF-\u03baB activation in dorsal root ganglion contributes to peripheral sensitization and chronic pain induced by oxaliplatin administration. Mol. Pain, 13.","DOI":"10.1177\/1744806917726256"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-04-1807","article-title":"Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates","volume":"11","author":"Jacobs","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"23426","DOI":"10.18632\/oncotarget.25193","article-title":"Oxaliplatin-induced blood brain barrier loosening: A new point of view on chemotherapy-induced neurotoxicity","volume":"9","author":"Branca","year":"2018","journal-title":"Oncotarget"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000443898","article-title":"Altered Expression of Cytoskeletal and Axonal Proteins in Oxaliplatin-Induced Neuropathy","volume":"97","author":"Sanna","year":"2016","journal-title":"Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10571-019-00667-7","article-title":"Neuroprotective Role of Selected Antioxidant Agents in Preventing Cisplatin-Induced Damage of Human Neurons In Vitro","volume":"39","author":"Klajn","year":"2019","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/0284186X.2017.1398836","article-title":"Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx\u00ae): A placebo-controlled randomised phase II study (PLIANT)","volume":"57","author":"Glimelius","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Piechotta, V., Jakob, T., Langer, P., Monsef, I., Scheid, C., Estcourt, L.J., Ocheni, S., Theurich, S., Kuhr, K., and Scheckel, B. (2019). Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: A network meta-analysis. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD013487"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS-341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Carozzi, V.A., Renn, C.L., Bardini, M., Fazio, G., Chiorazzi, A., Meregalli, C., Oggioni, N., Shanks, K., Quartu, M., and Serra, M.P. (2013). Bortezomib-Induced Painful Peripheral Neuropathy: An Electrophysiological, Behavioral, Morphological and Mechanistic Study in the Mouse. Plos One, 8.","DOI":"10.1371\/journal.pone.0072995"},{"key":"ref_103","first-page":"329","article-title":"Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: A meta-analysis","volume":"55","author":"Hu","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3892\/etm.2016.3738","article-title":"Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma","volume":"12","author":"Liu","year":"2016","journal-title":"Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Minarik, J., Pavlicek, P., Pour, L., Pika, T., Maisnar, V., Spicka, I., Jarkovsky, J., Krej\u010d\u00ed, M., Bacovsk\u00fd, J., and Radocha, J. (2015). Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy. Plos One, 10.","DOI":"10.1371\/journal.pone.0123866"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00520-015-2648-2","article-title":"Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib","volume":"23","author":"Peng","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_107","first-page":"1654","article-title":"Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Sub-cutaneous Injection of Bortezomib","volume":"27","author":"Liu","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1529-8027.2010.00287.x","article-title":"Bortezomib-induced inflammatory neuropathy","volume":"15","author":"Saifee","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","article-title":"A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma","volume":"22","author":"Magrangeas","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuro.2016.05.004","article-title":"Inhibition of the neuronal NF\u03baB pathway attenuates bortezomib-induced neuropathy in a mouse model","volume":"55","author":"Bruna","year":"2016","journal-title":"NeuroToxicology"},{"key":"ref_114","first-page":"3105","article-title":"Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and\/or thalidomide and is associated with severe neuropathy","volume":"24","author":"Wang","year":"2016","journal-title":"Support. Care Cancer"},{"key":"ref_115","first-page":"746","article-title":"Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: A genetic study based on a single nucleotide polymorphism array","volume":"35","author":"Alcoceba","year":"2016","journal-title":"Hematol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0753-3322(02)00168-3","article-title":"Thalidomide in multiple myeloma","volume":"56","author":"Richardson","year":"2002","journal-title":"Biomed. Pharm."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1021\/acs.chemrestox.7b00127","article-title":"The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage","volume":"30","author":"Wani","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/1042819031000067918","article-title":"Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma","volume":"44","author":"Wechalekar","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/10428190601001904","article-title":"An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma","volume":"48","author":"Prince","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00280-015-2863-z","article-title":"Mechanism of action of ixabepilone and its interactions with the \u03b2III-tubulin isotype","volume":"76","author":"Lopus","year":"2015","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.19.4.367","article-title":"Vincristine-induced neuropathy: A clinical study of fifty leukemic patients","volume":"19","author":"Sandier","year":"1969","journal-title":"Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Hou","year":"2018","journal-title":"Pain Manag."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/brain\/96.1.69","article-title":"Vincristine neuropathy","volume":"96","author":"Casey","year":"1973","journal-title":"Brain"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/02841860310020924","article-title":"Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel","volume":"43","author":"Scalone","year":"2004","journal-title":"Acta Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"425","DOI":"10.5306\/wjco.v8.i5.425","article-title":"Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer","volume":"8","author":"Kourie","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0971-5851.103152","article-title":"Successful treatment of vincristine induced ptosis and polyneuropathy with pyridoxine and pyridostigmine in a child with acute lymphoblastic leukemia","volume":"33","author":"Bhat","year":"2012","journal-title":"Indian J. Med Paediatr. Oncol. Off. J. Indian Soc. Med Paediatr. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3122\/jabfm.16.1.47","article-title":"Botanicals and dietary supplements in diabetic peripheral neuropathy","volume":"16","author":"Halat","year":"2003","journal-title":"J. Am. Board Fam. Pr."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2174\/092986712799320736","article-title":"Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development","volume":"19","author":"Ranieri","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/WCO.0b013e328364eb07","article-title":"Toxic and drug-induced peripheral neuropathies","volume":"26","author":"Diezi","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jpain.2019.06.011","article-title":"Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients","volume":"21","author":"Timmins","year":"2020","journal-title":"J. Pain"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1200\/JOP.2012.000863","article-title":"Impact of Chemotherapy-Induced Peripheral Neuropathy on Treatment Delivery in Nonmetastatic Breast Cancer","volume":"9","author":"Speck","year":"2013","journal-title":"J. Oncol. Pr."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3747\/co.21.1984","article-title":"The influence of chemotherapyinduced neurotoxicity on psychological distress and sleep disturbance in cancer patients","volume":"21","author":"Hong","year":"2014","journal-title":"Curr. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.clinph.2017.04.009","article-title":"Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer","volume":"128","author":"Kandula","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pain.2010.10.030","article-title":"Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline","volume":"152","author":"Xin","year":"2011","journal-title":"Pain"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.exer.2013.05.016","article-title":"Corneal innervation as a window to peripheral neuropathies","volume":"113","author":"Ferrari","year":"2013","journal-title":"Exp. Eye Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharm."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.pain.2014.03.022","article-title":"Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy","volume":"155","author":"Haroutounian","year":"2014","journal-title":"Pain"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.redox.2014.01.006","article-title":"Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy","volume":"2","author":"Areti","year":"2014","journal-title":"Redox Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1523\/JNEUROSCI.6343-11.2012","article-title":"Targeting the Overproduction of Peroxynitrite for the Prevention and Reversal of Paclitaxel-Induced Neuropathic Pain","volume":"32","author":"Doyle","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1074\/jbc.M409819200","article-title":"[Ca2+] Signaling between Mitochondria and Endoplasmic Reticulum in Neurons Is Regulated by Microtubules","volume":"280","author":"Mironov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","article-title":"Dysregulation of Cellular Calcium Homeostasis in Chemotherapy-Evoked Painful Peripheral Neuropathy","volume":"102","author":"Siau","year":"2006","journal-title":"Anesth. Analg."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1744806917714693","DOI":"10.1177\/1744806917714693","article-title":"Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy","volume":"13","author":"Aromolaran","year":"2017","journal-title":"Mol. Pain"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/S12094-010-0474-z","article-title":"Chemotherapy-induced peripheral neuropathy: Clinical features, diagnosis, prevention and treatment strategies","volume":"12","author":"Sereno","year":"2010","journal-title":"Clin. Transl. Oncol."},{"key":"ref_147","first-page":"1534735419886662","article-title":"The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis","volume":"18","author":"Chien","year":"2019","journal-title":"Integr. Cancer."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"11074","DOI":"10.1523\/JNEUROSCI.3708-15.2016","article-title":"CD8+ T Cells and Endogenous IL-10 Are Required for Resolution of Chemothera-py-Induced Neuropathic Pain","volume":"36","author":"Krukowski","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1188\/07.CJON.901-913","article-title":"Putting Evidence Into Practice\u00ae: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy","volume":"11","author":"Visovsky","year":"2007","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological Management of Chronic Neuropathic Pain: Revised Consensus Statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res. Manag."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1007\/s00520-014-2158-7","article-title":"A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors","volume":"22","author":"Gewandter","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2010","journal-title":"Support. Care Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00520-015-2642-8","article-title":"Cancer treatment-related neuropathic pain: Proof of concept study with menthol\u2014a TRPM8 agonist","volume":"23","author":"Fallon","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10549-017-4437-8","article-title":"Long-term peripheral neuropathy symptoms in breast cancer survivors","volume":"166","author":"Ali","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_157","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: A critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"Ca: A Cancer J. Clin."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/toxics3020198","article-title":"Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN)","volume":"3","author":"Canta","year":"2015","journal-title":"Toxics"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2020.11951","article-title":"PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)","volume":"20","author":"Loizzi","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2174\/0929867053764635","article-title":"Metals, Toxicity and Oxidative Stress","volume":"12","author":"Valko","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.201108111","article-title":"Axon degeneration: Molecular mechanisms of a self-destruction pathway","volume":"196","author":"Wang","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.12.006","article-title":"Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy","volume":"73","author":"Lees","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/j.1532-2149.2012.00219.x","article-title":"The contribution of satellite glial cells to chemotherapy-induced neuropathic pain","volume":"17","author":"Warwick","year":"2012","journal-title":"Eur. J. Pain"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1159\/000495828","article-title":"Blocking TRPA1 and TNF-\u03b1 Signal Improves Bortezomib-Induced Neuropathic Pain","volume":"51","author":"Li","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1523\/JNEUROSCI.3858-05.2006","article-title":"Acute p38-Mediated Modulation of Tetrodotoxin-Resistant Sodium Channels in Mouse Sensory Neurons by Tumor Necrosis Factor-","volume":"26","author":"Jin","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neuroscience.2015.06.016","article-title":"Chemotherapy, cognitive impairment and hippocampal toxicity","volume":"309","author":"Dietrich","year":"2015","journal-title":"Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/acn3.121","article-title":"Systemic chemotherapy decreases brain glucose metabolism","volume":"1","author":"Horky","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1053\/j.seminoncol.2011.03.014","article-title":"An Update on Cancer- and Chemotherapy-Related Cognitive Dysfunction: Current Status","volume":"38","author":"Janelsins","year":"2011","journal-title":"Semin. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.2015.62.1276","article-title":"Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy","volume":"34","author":"Nudelman","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Rochfort, K.D., Collins, L.E., Murphy, R.P., and Cummins, P.M. (2014). Downregulation of Blood-Brain Barrier Phenotype by Proinflammatory Cytokines Involves NADPH Oxidase-Dependent ROS Generation: Consequences for Interendothelial Adherens and Tight Junctions. Plos One, 9.","DOI":"10.1371\/journal.pone.0101815"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.4049\/jimmunol.177.8.5574","article-title":"IL-1\u03b2 Regulates Blood-Brain Barrier Permeability via Reactivation of the Hypoxia-Angiogenesis Program","volume":"177","author":"Argaw","year":"2006","journal-title":"J. Immunol."},{"key":"ref_174","first-page":"571","article-title":"Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations","volume":"21","author":"Hou","year":"2018","journal-title":"Pain Physician"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.clnu.2013.04.007","article-title":"Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): A systematic review","volume":"32","author":"Schloss","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms","volume":"17","author":"Hu","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1200\/JCO.2005.07.167","article-title":"Randomized Trial of Amifostine in Locally Advanced Non\u2013Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01","volume":"23","author":"Movsas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-52248-9","article-title":"Evidence that fodipir (DPDP) binds neurotoxic Pt2+ with a high affinity: An electron paramagnetic resonance study","volume":"9","author":"Stehr","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/85879","article-title":"Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I","volume":"27","author":"Dawkins","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1523\/JNEUROSCI.3127-04.2005","article-title":"Activation of Nuclear Factor-B via Endogenous Tumor Necrosis Factor Regulates Survival of Axotomized Adult Sensory Neurons","volume":"25","author":"Fernyhough","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2014","journal-title":"Hematol. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/acn3.90","article-title":"Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients","volume":"1","author":"Ebenezer","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U","article-title":"Damage to The Cytoskeleton of Large Diameter Sensory Neurons and Myelin-ated Axons in Vincristine-Induced Painful Peripheral Neuropathy in The Rat","volume":"424","author":"Topp","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.20057","article-title":"Painful peripheral neuropathy and its nonsurgical treatment","volume":"30","author":"Wolfe","year":"2004","journal-title":"Muscle Nerve"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2165\/00002018-199106040-00007","article-title":"Prevention and Management of Drug-Induced Peripheral Neuropathy","volume":"6","author":"Olesen","year":"1991","journal-title":"Drug Saf."},{"key":"ref_187","first-page":"673","article-title":"Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program","volume":"45","author":"Posner","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nchembio.1212","article-title":"ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system","volume":"9","author":"Polier","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Ranieri, G., Marech, I., Niccoli-Asabella, A., Di Palo, A., Porcelli, M., Lavelli, V., Rubini, G., Ferrari, C., and Gadaleta, P. (2017). Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET\/CT in Response Evaluation. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091937"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.critrevonc.2013.08.012","article-title":"Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma","volume":"89","author":"Ranieri","year":"2014","journal-title":"Crit. Rev. Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.critrevonc.2013.05.009","article-title":"Tyrosine kinase inhibitors (TKIs) in human and pet tumours with special reference to breast cancer: A comparative review","volume":"88","author":"Ranieri","year":"2013","journal-title":"Crit. Rev. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14656566.2019.1645121","article-title":"An evaluation of masitinib for treating systemic mastocytosis","volume":"20","author":"Laforgia","year":"2019","journal-title":"Expert Opin. Pharm."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.critrevonc.2013.12.011","article-title":"Masitinib (AB1010), from canine tumor model to human clinical development: Where we are?","volume":"91","author":"Marech","year":"2014","journal-title":"Crit. Rev. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/14656566.2020.1744566","article-title":"Pharmacotherapy in Mast Cell Leukemia","volume":"21","author":"Laforgia","year":"2020","journal-title":"Expert Opin. Pharm."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3892\/ol.2014.2376","article-title":"Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study","volume":"8","author":"Infusino","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"590707","DOI":"10.3389\/fonc.2020.590707","article-title":"Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study","volume":"10","author":"Ranieri","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1093\/brain\/aws145","article-title":"Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy","volume":"135","author":"Verheyen","year":"2012","journal-title":"Brain"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11060-015-2049-x","article-title":"Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy","volume":"127","author":"Saad","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Chiaramonte, R., Romano, M., and Vecchio, M. (2020). A Systematic Review of the Diagnostic Methods of Small Fiber Neuropathies in Rehabilitation. Diagn., 10.","DOI":"10.3390\/diagnostics10090613"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Vecchio, M., Chiaramonte, R., Romano, M., Pavone, P., Musumeci, G., and Mauro, G.L. (2020). A Systematic Review of Pharmacologic and Rehabilitative Treatment of Small Fiber Neuropathies. Diagn., 10.","DOI":"10.3390\/diagnostics10121022"},{"key":"ref_201","first-page":"450","article-title":"Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy","volume":"101","author":"Chua","year":"2016","journal-title":"Clin. Pharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1980\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:25:15Z","timestamp":1760160315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/4\/1980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":201,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ijms22041980"],"URL":"https:\/\/doi.org\/10.3390\/ijms22041980","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]}}}